News | BTG Specialty Pharmaceuticals

Date

Title

19 Oct 2022

SERB presents preclinical data showing initial efficacy of COVID-19 treatment developed with polyclonal antibody platform
14 Jul 2022

SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote

SERB will leverage its unique broad spectrum polyclonal antibody platform, gained in its acquisition of BTG Specialty Pharmaceuticals
09 Jun 2022

Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022
11 Apr 2022

Thomas Kolaras Joins SERB and BTG Specialty Pharmaceuticals as US Chief Commercial Officer
04 Apr 2022

SERB acquires the rights to Xermelo® outside US and Japan for Carcinoid Syndrome Diarrhoea
14 Jan 2022

SERB receives EU approval for Voraxaze® (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity

Voraxaze® is now authorized for marketing in all members states of the European Union.